Movement Disorders

Filter Your Results

 

News

 

Topline Results From Phase 2a Study for Cannibinoid for Treating Tourette Syndrome

Monday, April 09, 2018—Therapix Biosciences (Tel Aviv, Israel) has announced results from its investigator-initiated phase 2a study at Yale University led by Michael Bloch and James Leckman to test …

New Wearable Tracker With Objective Measurements Improves Quality of Life and Clinical Outcomes for 43% of Patients with Parkinson’s Disease

Tuesday, April 03, 2018—Using the Personal Kinetigraph (PKG) smart watch (Global Kinetics Corporation, Ltd; Portsmouth, NH), which is a Food and Drug Administration (FDA)-cleared technology, research…

Multiple System Atrophy-D Maybe Something Altogether–Different

Jill Giordano Farmer, DO, MPH

March/April 2018—A report from the 6th International Congress on Multisystem Atrophy.

Phase 1 Trial Initiated for Product Candidate CAD-1883, Hoped to Provide Treatment for Spinocerebellar Ataxia and Essential Tremor

Monday, March 12, 2018—Novel therapeutics developer, Cadent Therapeutics (Cambridge, Massachusetts) has initiated a phase 1 clinical trial for product candidate CAD-1883, which is an allosteric modu…

Biosimilar Being Developed for Botox

Thursday, March 01, 2018—In a transatlantic collaboration, Mylan N.V. (Pittsburgh, Pennsylvania) and Revance Therapeutics, Inc. (Hertsfordshire, England) have reached an agreement to collaborate on th…

Kenneth Marek, MD Joins the Michael J. Fox Foundation for Parkinson's Research as Scientific Advisor

Tuesday, February 27, 2018—The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced that Kenneth Marek, MD, has joined the Foundation as Scientific Advisor. In this role, Dr. Mar…

Tears May Contain a Biomarker for Parkinson's Disease

Thursday, February 22, 2018—A preliminary study will be presented at the American Academy of Neurology (AAN) meeting in Los Angeles, April 21-27, that shows there may be a biomarker in tears for Parkinso…

Food and Drug Administration Approves Extended-Release Amantadine for Treatment of Parkinson's Disease and Drug-Induced Extrapyramidal Reactions in Adults

Tuesday, February 20, 2018—The Food and Drug Administration (FDA) approved Osmolex ER (Osmotica Pharmaceuticals; Bridgewater, NJ) an extended-release formulation of amantadine for the treatment of Parki…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC